MX2023009786A - Injertos bioactivos dinamicos y usos terapeuticos de los mismos despues de lesion del cns. - Google Patents
Injertos bioactivos dinamicos y usos terapeuticos de los mismos despues de lesion del cns.Info
- Publication number
- MX2023009786A MX2023009786A MX2023009786A MX2023009786A MX2023009786A MX 2023009786 A MX2023009786 A MX 2023009786A MX 2023009786 A MX2023009786 A MX 2023009786A MX 2023009786 A MX2023009786 A MX 2023009786A MX 2023009786 A MX2023009786 A MX 2023009786A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic uses
- cns injury
- pas
- bioactive scaffolds
- dynamic bioactive
- Prior art date
Links
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 230000000975 bioactive effect Effects 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000000712 assembly Effects 0.000 abstract 3
- 238000000429 assembly Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 108010088381 isoleucyl-lysyl-valyl-alanyl-valine Proteins 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163152498P | 2021-02-23 | 2021-02-23 | |
| PCT/US2022/017490 WO2022182737A2 (en) | 2021-02-23 | 2022-02-23 | Dynamic bioactive scaffolds and therapeutic uses thereof after cns injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009786A true MX2023009786A (es) | 2023-10-09 |
Family
ID=83048442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009786A MX2023009786A (es) | 2021-02-23 | 2022-02-23 | Injertos bioactivos dinamicos y usos terapeuticos de los mismos despues de lesion del cns. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240325548A1 (https=) |
| EP (1) | EP4298111A4 (https=) |
| JP (1) | JP2024507871A (https=) |
| KR (1) | KR20230148425A (https=) |
| AU (1) | AU2022227585A1 (https=) |
| CA (1) | CA3209358A1 (https=) |
| IL (1) | IL305375A (https=) |
| MX (1) | MX2023009786A (https=) |
| WO (1) | WO2022182737A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118072851A (zh) * | 2024-04-24 | 2024-05-24 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种基于粗粒化分子动力学模拟的自组装肽结构预测方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003070749A2 (en) * | 2002-02-15 | 2003-08-28 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| US7166574B2 (en) * | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
| US8227411B2 (en) * | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
| US7544661B2 (en) * | 2003-12-05 | 2009-06-09 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| US7671012B2 (en) * | 2004-02-10 | 2010-03-02 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
| WO2006014530A2 (en) * | 2004-07-07 | 2006-02-09 | The General Hospital Corporation | Imaging of enzyme activity |
| AU2006206194A1 (en) * | 2005-01-21 | 2006-07-27 | Northwestern University | Methods and compositions for encapsulation of cells |
| WO2006096614A2 (en) * | 2005-03-04 | 2006-09-14 | Northwestern University | Angiogenic heparin binding peptide amphiphiles |
| US9457064B2 (en) * | 2005-07-29 | 2016-10-04 | Abburi Ramaiah | Method for treatment of vitiligo |
| AU2006290251B2 (en) * | 2005-09-13 | 2011-12-08 | Abburi Ramaiah | Agonist peptides of basic fibroblast growth factor (BFGF) and the method of reduction of wrinkle on skin, darkening of hair and acceleration of wound healing |
| WO2008039483A2 (en) * | 2006-09-26 | 2008-04-03 | Massachusetts Institute Of Technology | Modified self-assembling peptides |
| US8772228B2 (en) * | 2007-02-14 | 2014-07-08 | Northwestern University | Aligned nanofibers and related methods of use |
| EP2310035B1 (en) * | 2008-06-16 | 2015-08-26 | University Of Rochester | Fibroblast growth factor (fgf) analogs and uses thereof |
| US20170021056A1 (en) * | 2015-07-20 | 2017-01-26 | Northwestern University | Peptide amphiphile biomaterials for nerve repair |
| WO2019195741A1 (en) * | 2018-04-06 | 2019-10-10 | Northwestern University | Bdnf mimetic peptide amphiphiles |
| WO2020097460A1 (en) * | 2018-11-09 | 2020-05-14 | Northwestern University | Self-assembling vegf nanoparticles |
| WO2020154631A1 (en) * | 2019-01-24 | 2020-07-30 | Northwestern University | Dynamics within supramolecular 1kvav matrices enhance functional maturation of human ipscs-der1ved neurons and regeneration |
-
2022
- 2022-02-23 EP EP22760324.8A patent/EP4298111A4/en active Pending
- 2022-02-23 AU AU2022227585A patent/AU2022227585A1/en active Pending
- 2022-02-23 KR KR1020237032897A patent/KR20230148425A/ko active Pending
- 2022-02-23 WO PCT/US2022/017490 patent/WO2022182737A2/en not_active Ceased
- 2022-02-23 IL IL305375A patent/IL305375A/en unknown
- 2022-02-23 JP JP2023550590A patent/JP2024507871A/ja active Pending
- 2022-02-23 CA CA3209358A patent/CA3209358A1/en active Pending
- 2022-02-23 US US18/278,068 patent/US20240325548A1/en active Pending
- 2022-02-23 MX MX2023009786A patent/MX2023009786A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4298111A4 (en) | 2025-01-15 |
| KR20230148425A (ko) | 2023-10-24 |
| JP2024507871A (ja) | 2024-02-21 |
| WO2022182737A3 (en) | 2022-12-15 |
| CA3209358A1 (en) | 2022-09-01 |
| US20240325548A1 (en) | 2024-10-03 |
| AU2022227585A1 (en) | 2023-09-14 |
| IL305375A (en) | 2023-10-01 |
| WO2022182737A2 (en) | 2022-09-01 |
| EP4298111A2 (en) | 2024-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521421897B1 (ar) | تركيبة تعتمد على جزء من نباتات طبية أو مستخلصاتها واستخداماتها ومنتجاتها | |
| PH12022551379A1 (en) | Substituted tetrahydrofurans as modulators of sodium channels | |
| CR20220642A (es) | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 | |
| AR033592A1 (es) | Composicion de tratamiento de las fibras queratinicas que comprende un polimero poliuretano asociativo cationico y un agente protector o acondicionador | |
| CL2024002956A1 (es) | Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo. | |
| PH12023552741A1 (en) | Psilocybin Compositions, Methods Of Making And Methods Of Using The Same | |
| ES2157601T3 (es) | Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple. | |
| GB9807639D0 (en) | Anti-inflammatory agents | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| CL2024003232A1 (es) | Compuestos derivados de heteroarilo y uso para tratar el dolor. | |
| CL2024003231A1 (es) | Compuestos derivados de heteroarilo y uso para tratar el dolor. | |
| MX2023009786A (es) | Injertos bioactivos dinamicos y usos terapeuticos de los mismos despues de lesion del cns. | |
| EP1628667A4 (en) | METHOD FOR TREATING DISEASES USING HSP90 INHIBITION AGENTS COMBINED WITH ANTIMITOTICS | |
| Jones et al. | Efficacy of Emotional Freedom Techniques (EFT) in reducing public speaking anxiety: A randomized controlled trial | |
| CY1119190T1 (el) | Χρηση αναστολεων της il-18 για αγωγη ή προληψη βλαβων του κνς | |
| AR096355A1 (es) | Composición odontológica de papaína en gel para el tratamiento atraumático de caries y método para prepararla | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| CR7271A (es) | Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno | |
| GEAP202215466A (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment | |
| EP4234022A3 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| CO2024002715A2 (es) | Formulaciones de radiprodil | |
| MX2024015613A (es) | Composicion farmaceutica que comprende salbutamol | |
| MX2022009448A (es) | Inhibidor de micro ácido ribonucleico 485 (miarn-485) para regulación génica por incremento. | |
| WO2019135215A3 (en) | Herbal extracts for treatment of herpesvirus infections |